CCHR reviews psychiatric research in light of the “chemical imbalance causes depression” theory being debunked, but finds millions of dollars being wasted studying animal brains…
All of the panel members that produced the American Psychiatric Association (APA)’s Practice Guideline for the Treatment of Patients with Major Depressive Disorder had numerous financial ties to drug companies that manufacture antidepressants, raising questions about the trustworthiness of the guideline, a UMass Boston researcher says.
All of the panel members that produced the American Psychiatric Association (APA)’s Practice Guideline for the Treatment of Patients with Major Depressive Disorder had numerous financial ties to drug companies that manufacture antidepressants, raising questions about the trustworthiness of the guideline, a UMass Boston researcher says.
Recently some of the nation’s top researchers, clinicians and scientists convened in Washington D.C. for the first annual Selling Sickness conference–examining how Pharma “sells” diseases to move the medications intended to treat them. Examples of Pharma’s disease-mongering business model abound, especially since direct-to-consumer advertising began in the late 1990’s.
The pharmaceutical companies have broadened their horizon. It is not enough that they have 30% of middle and upper income white women addicted to antidepressants and that 20% of adults take some form of psychiatric medication. They now want to hook as many children as possible on psychiatric medication as well.